Welcome to Advanced Search

Models

About 99 results
Literature

CRISPR/Cas9‑mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice

Model Organisms:Mouse Product & Service:F9 Research field:Hemophilia

Literature

Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

Model Organisms:小鼠 Product & Service:PRKAG2 H530R Research field:Heart

室性心律失常 AAV9 基因治疗

Literature

In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR–dCas9- activator...

Model Organisms:小鼠 Product & Service:- Research field:Gene regulation

Pages

SMOC Launched U-HuDTMbase®, Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, to Accelerate Novel Drug Discovery

U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.

Pages

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

F0 homozygous mice gene knockout Crispr/Cas projects immediate phenotype analysis research efficiency cost optimization.

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Pages

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

CRISPR-Cas9 technology Broad Institute genetically modified mouse

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Email Back to top